A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

NCT02616640 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Durvalumab
DRUG: Pomalidomide
DRUG: Dexamethasone

Sponsor

Celgene